214 related articles for article (PubMed ID: 26347041)
1. Long-term outcome of myotonia associated with hyperadrenocorticism in 2 dogs.
Nagata N; Yuki M
Can Vet J; 2015 Sep; 56(9):931-3. PubMed ID: 26347041
[TBL] [Abstract][Full Text] [Related]
2. Adrenocorticotropic hormone levels in dogs with pituitary-dependent hyperadrenocorticism following trilostane therapy.
Witt AL; Neiger R
Vet Rec; 2004 Mar; 154(13):399-400. PubMed ID: 15083974
[No Abstract] [Full Text] [Related]
3. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism.
Alenza DP; Arenas C; Lopez ML; Melian C
J Am Anim Hosp Assoc; 2006; 42(4):269-76. PubMed ID: 16822765
[TBL] [Abstract][Full Text] [Related]
4. Trilostane in dogs.
Ramsey IK
Vet Clin North Am Small Anim Pract; 2010 Mar; 40(2):269-83. PubMed ID: 20219488
[TBL] [Abstract][Full Text] [Related]
5. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Braddock JA; Church DB; Robertson ID; Watson AD
Aust Vet J; 2003 Oct; 81(10):600-7. PubMed ID: 15080470
[TBL] [Abstract][Full Text] [Related]
6. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Mantis P; Lamb CR; Witt AL; Neiger R
Vet Radiol Ultrasound; 2003; 44(6):682-5. PubMed ID: 14703251
[TBL] [Abstract][Full Text] [Related]
7. Trismus due to myotonia associated with hyperadrenocorticism in a dog.
Yokota S; Kobatake Y; Maekawa M; Takashima S; Nishii N
J Vet Med Sci; 2023 Aug; 85(8):876-879. PubMed ID: 37357395
[TBL] [Abstract][Full Text] [Related]
8. Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane.
Reusch CE; Sieber-Ruckstuhl N; Wenger M; Lutz H; Perren A; Pospischil A
Vet Rec; 2007 Feb; 160(7):219-24. PubMed ID: 17308018
[TBL] [Abstract][Full Text] [Related]
9. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Survival Times for Dogs with Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated.
Nagata N; Kojima K; Yuki M
J Vet Intern Med; 2017 Jan; 31(1):22-28. PubMed ID: 27906457
[TBL] [Abstract][Full Text] [Related]
12. The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Kenefick SJ; Neiger R
J Small Anim Pract; 2008 Mar; 49(3):139-43. PubMed ID: 18086154
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
14. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Ruckstuhl NS; Nett CS; Reusch CE
Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Vaughan MA; Feldman EC; Hoar BR; Nelson RW
J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
Cook AK; Bond KG
J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
[TBL] [Abstract][Full Text] [Related]
18. Use of trilostane for the treatment of pituitary-dependent hyperadrenocorticism in a cat.
Skelly BJ; Petrus D; Nicholls PK
J Small Anim Pract; 2003 Jun; 44(6):269-72. PubMed ID: 12831104
[TBL] [Abstract][Full Text] [Related]
19. The use of trilostane for the treatment of alopecia X in Alaskan malamutes.
Leone F; Cerundolo R; Vercelli A; Lloyd DH
J Am Anim Hosp Assoc; 2005; 41(5):336-42. PubMed ID: 16141187
[TBL] [Abstract][Full Text] [Related]
20. Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.
Bonadio CM; Feldman EC; Cohen TA; Kass PH
J Vet Intern Med; 2014; 28(4):1239-43. PubMed ID: 24863172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
